Low responsiveness of peripheral lymphocytes in extraparenchymal neurocysticercosis.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
19
01
2023
accepted:
16
05
2023
revised:
13
06
2023
medline:
15
6
2023
pubmed:
1
6
2023
entrez:
1
6
2023
Statut:
epublish
Résumé
The morbidity and mortality of extraparenchymal neurocysticercosis (EP-NC) remain high and effectiveness of current medical treatment is suboptimal. Various factors have been implicated in the severity of EP-NC and in the poor response to treatment, but the possible role of host immune and endocrine systems has not yet been examined thoroughly. 42 participants with EP-NC before receiving standard treatment and 25 healthy controls were included in the study. Treatment response was assessed by comparing pre/post treatment parasite volumes from 3D MRI. Prior to treatment among participants with EP-NC, specific stimulation induced an increased specific proliferative response accompanied by a significant increase in IL-4, NK, NKT, Bregs and Tregs cells, whereas in healthy controls, specific stimulation induced a significant increase in IL-1β, IL-5, CCL5, IL-6, TNF-α, NK and Bregs cells. Significant differences between participants with EP-NC and healthy controls in the specific inflammatory response were observed. Participants with EP-NC prior to treatment had significantly weaker responses of proinflammatory cytokines (IL-6, TNF-α) and NK cells, and stronger IL-4 response. Anthelmintic treatment did not promote significant peripheral immunological changes at any time, although inflammation was sustained in the cerebrospinal fluid. Serum estradiol concentration significantly decreased after anthelmintic treatment among males, and cortisol correlated negatively with IL-6 and positively with IFN-γ levels. No pre-treatment immunologic or endocrinologic parameters were significantly associated with response to treatment. Prior to anthelmintic treatment, EP-NC was characterized by low lymphocyte reactivity accompanied by a regulatory response, which may be involved in the lack of peripheral immunological changes during and after treatment, although a central inflammatory response was present. This weak specific peripheral response could favor the chronicity of the infection and the poor response to treatment. Our findings highlight the need for new anti-inflammatory treatment focused on the central nervous system with less systemic immunosuppressive effects.
Sections du résumé
BACKGROUND
The morbidity and mortality of extraparenchymal neurocysticercosis (EP-NC) remain high and effectiveness of current medical treatment is suboptimal. Various factors have been implicated in the severity of EP-NC and in the poor response to treatment, but the possible role of host immune and endocrine systems has not yet been examined thoroughly.
METHODOLOGY/PRINCIPAL FINDINGS
42 participants with EP-NC before receiving standard treatment and 25 healthy controls were included in the study. Treatment response was assessed by comparing pre/post treatment parasite volumes from 3D MRI. Prior to treatment among participants with EP-NC, specific stimulation induced an increased specific proliferative response accompanied by a significant increase in IL-4, NK, NKT, Bregs and Tregs cells, whereas in healthy controls, specific stimulation induced a significant increase in IL-1β, IL-5, CCL5, IL-6, TNF-α, NK and Bregs cells. Significant differences between participants with EP-NC and healthy controls in the specific inflammatory response were observed. Participants with EP-NC prior to treatment had significantly weaker responses of proinflammatory cytokines (IL-6, TNF-α) and NK cells, and stronger IL-4 response. Anthelmintic treatment did not promote significant peripheral immunological changes at any time, although inflammation was sustained in the cerebrospinal fluid. Serum estradiol concentration significantly decreased after anthelmintic treatment among males, and cortisol correlated negatively with IL-6 and positively with IFN-γ levels. No pre-treatment immunologic or endocrinologic parameters were significantly associated with response to treatment.
CONCLUSION/SIGNIFICANCE
Prior to anthelmintic treatment, EP-NC was characterized by low lymphocyte reactivity accompanied by a regulatory response, which may be involved in the lack of peripheral immunological changes during and after treatment, although a central inflammatory response was present. This weak specific peripheral response could favor the chronicity of the infection and the poor response to treatment. Our findings highlight the need for new anti-inflammatory treatment focused on the central nervous system with less systemic immunosuppressive effects.
Identifiants
pubmed: 37262055
doi: 10.1371/journal.pntd.0011386
pii: PNTD-D-23-00087
pmc: PMC10263342
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
Interleukin-4
207137-56-2
Interleukin-6
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0011386Informations de copyright
Copyright: © 2023 Romo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Immunol Res. 2016;2016:2395645
pubmed: 27563682
Int J Parasitol. 2012 Feb;42(2):171-6
pubmed: 22233829
J Clin Pharmacol. 2019 Apr;59(4):548-556
pubmed: 30476351
Front Immunol. 2018 Mar 08;9:478
pubmed: 29662485
J Steroid Biochem Mol Biol. 2005 May;95(1-5):63-9
pubmed: 16019206
Stroke. 1997 Jan;28(1):211-3
pubmed: 8996514
Am J Trop Med Hyg. 2021 Jul 7;105(1):176-180
pubmed: 34232912
Breast Cancer Res. 2002;4(2):65-9
pubmed: 11879566
Cancer Res. 2006 Nov 1;66(21):10497-504
pubmed: 17079471
Expert Rev Anti Infect Ther. 2011 Jan;9(1):123-33
pubmed: 21171883
Expert Rev Anti Infect Ther. 2021 Dec;19(12):1503-1518
pubmed: 33794119
J Parasitol. 2012 Feb;98(1):142-8
pubmed: 21955298
Clin Infect Dis. 2021 May 4;72(9):e326-e333
pubmed: 33269789
Ann Neurol. 2016 Sep;80(3):434-42
pubmed: 27438337
Clin Exp Immunol. 2016 Feb;183(2):271-9
pubmed: 26391104
Trop Geogr Med. 1988 Apr;40(2):143-6
pubmed: 3407004
Exp Parasitol. 2020 Jan;208:107801
pubmed: 31730781
Acta Trop. 2015 Dec;152:60-65
pubmed: 26327445
PLoS Negl Trop Dis. 2015 Oct 27;9(10):e0004143
pubmed: 26506532
Am J Trop Med Hyg. 2020 Jan;102(1):78-89
pubmed: 31642423
Exp Parasitol. 2013 Aug;134(4):443-6
pubmed: 23684909
Expert Rev Neurother. 2018 Oct;18(10):743-747
pubmed: 30185077
Front Immunol. 2018 Nov 16;9:2652
pubmed: 30505305
Med Microbiol Immunol. 2014 Dec;203(6):373-81
pubmed: 24957954
Am J Trop Med Hyg. 2018 Apr;98(4):945-966
pubmed: 29644966
J Travel Med. 2012 Mar-Apr;19(2):112-7
pubmed: 22414036
Neurology. 2006 Feb 14;66(3):436-8
pubmed: 16382035
Int J Parasitol. 2005 Nov;35(13):1349-58
pubmed: 16126211
PLoS Negl Trop Dis. 2020 Apr 16;14(4):e0008005
pubmed: 32298263
Microbes Infect. 2006 Apr;8(4):1082-9
pubmed: 16520076
J Neuroimmunol. 2006 Apr;173(1-2):45-55
pubmed: 16406118
PLoS Negl Trop Dis. 2017 Jun 2;11(6):e0005624
pubmed: 28575043